Home LiteratureArticle Details
PMID: 26639197 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

Cancer letters ·Vol. 371 ·No. 1 ·2016-02-01 ·Pages 117-24

Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, Gabrilovich DI, Nefedova Y

Abstract

Multiple myeloma (MM) is an incurable cancer of plasma cells localized preferentially in the bone marrow (BM). Resistance to chemotherapy represents one of the main challenges in MM management. BM microenvironment is known to play a critical role in protection of MM cells from chemotherapeutics; however, mechanisms responsible for this effect are largely unknown. Development of MM is associated with accumulation of myeloid-derived suppressor cells (MDSCs) mostly represented by pathologically activated relatively immature polymorphonuclear neutrophils (PMN-MDSCs). Here, we investigated whether PMN-MDSCs are responsible for BM microenvironment-mediated MM chemoresistance. Using in vivo mouse models allowing manipulation of myeloid cell number, we demonstrated a critical role for myeloid cells in MM growth and chemoresistance. PMN-MDSCs isolated from MM-bearing host are immunosuppressive and thus, functionally distinct from their counterpart in tumor-free host neutrophils. We found, however, that both PMN-MDSCs and neutrophils equally promote MM survival from doxorubicin and melphalan and that this effect is mediated by soluble factors rather than direct cell-cell contact. Our data indicate that targeting PMN-MDSCs would enhance chemotherapy efficacy in MM.

Keywords
Chemoresistance Multiple myeloma Myeloid-derived suppressor cells Neutrophils
MeSH Terms
Animals Antibiotics, Antineoplastic/pharmacology Antineoplastic Agents, Alkylating/pharmacology Apoptosis/drug effects Cell Line, Tumor Cell Lineage Coculture Techniques Disease Models, Animal Doxorubicin/pharmacology Drug Resistance, Neoplasm Humans Melphalan/pharmacology Mice, Inbred C57BL Multiple Myeloma/drug therapy,metabolism,pathology Myeloid Cells/drug effects,metabolism,pathology Neutrophils/drug effects,metabolism,pathology Paracrine Communication Phenotype Time Factors Tumor Cells, Cultured Tumor Microenvironment
Chemicals
Antibiotics, Antineoplastic Antineoplastic Agents, Alkylating Doxorubicin Melphalan
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Ramachandran Indu R
Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA; Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Condamine Thomas
Translational Tumor Immunology Program, The Wistar Institute, Philadelphia, PA, USA; Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Lin Cindy
Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Herlihy Sarah E
Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
Garfall Alfred
Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Vogl Dan T
Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Gabrilovich Dmitry I
Translational Tumor Immunology Program, The Wistar Institute, Philadelphia, PA, USA; Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Nefedova Yulia
Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA; Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: [email protected].
References (30)
30 references, click to expand
  1. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.
    Blood. 2009 Oct 22;114(17):3625-8 PMID: 19710503
  2. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
    Blood. 2013 Apr 11;121(15):2975-87 PMID: 23321256
  3. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line.
    Exp Cell Res. 1999 Jun 15;249(2):269-78 PMID: 10366426
  4. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Cancer Lett. 2010 Sep 1;295(1):110-23 PMID: 20236757
  5. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
    J Clin Invest. 2014 Jun;124(6):2626-39 PMID: 24789911
  6. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
    Br J Cancer. 2003 Jun 2;88(11):1721-6 PMID: 12771987
  7. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.
    J Immunol. 2013 Apr 1;190(7):3815-23 PMID: 23460744
  8. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
    J Immunol. 2011 Aug 1;187(3):1243-53 PMID: 21715687
  9. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.
    Gene Ther. 1999 Jul;6(7):1258-66 PMID: 10455434
  10. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
    Cancer Cell. 2009 Oct 6;16(4):309-23 PMID: 19800576
  11. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.
    Blood. 1996 Feb 1;87(3):1056-63 PMID: 8562930
  12. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  13. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.
    Scand J Immunol. 2010 Dec;72(6):540-7 PMID: 21044128
  14. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Leukemia. 2003 Jun;17(6):1175-82 PMID: 12764386
  15. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors.
    Br J Haematol. 1997 May;97(2):429-40 PMID: 9163610
  16. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow.
    Leukemia. 2012 Nov;26(11):2424-8 PMID: 22522789
  17. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.
    Leukemia. 2013 Mar;27(3):702-10 PMID: 22996336
  18. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.
    Oncogene. 2001 Sep 20;20(42):5991-6000 PMID: 11593406
  19. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.
    Blood. 2004 Oct 15;104(8):2484-91 PMID: 15187021
  20. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
    Blood. 1999 Mar 1;93(5):1658-67 PMID: 10029595
  21. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.
    Leuk Lymphoma. 2014 Dec;55(12):2893-900 PMID: 24625328
  22. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells.
    Blood. 1998 Nov 1;92(9):3381-7 PMID: 9787177
  23. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer.
    Cancer Immunol Immunother. 2013 Mar;62(3):405-10 PMID: 23423351
  24. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer.
    Cancer Immunol Immunother. 2011 Mar;60(3):419-23 PMID: 20976448
  25. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Cytokine. 2011 Nov;56(2):365-75 PMID: 21742513
  26. Combined modality immunotherapy and chemotherapy: a new perspective.
    Cancer Immunol Immunother. 2008 Oct;57(10):1523-9 PMID: 18488219
  27. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.
    J Clin Invest. 2004 Jun;113(12):1763-73 PMID: 15199411
  28. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
    Mol Cell Biol. 1988 Jan;8(1):466-72 PMID: 2827008
  29. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells.
    Clin Cancer Res. 1996 Aug;2(8):1307-13 PMID: 9816301
  30. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.
    Cancer Immunol Immunother. 2013 May;62(5):909-18 PMID: 23589106
Article Info
Journal
Cancer letters
Abbr.
Cancer Lett
ISSN
1872-7980
Published
2016-02-01
Epub
2015-00-27
Pages
117-24
Language
English
Region
Ireland
NLM ID
7600053
PMCID
PMC4919899
Subset
IM
Grants
NCI NIH HHS · T32CA009171 · United States
NCI NIH HHS · P30-CA76292 · United States
NCI NIH HHS · P30 CA010815 · United States
NCI NIH HHS · P30 CA076292 · United States
NCI NIH HHS · CA010815 · United States
NCI NIH HHS · T32 CA009171 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]